GlassScriptPhysician profile
Misha Masumy
NPI 1811511405
$1,664.27
in general payments reported to CMS, 2019-2025
20 companies · $368 in 2025
The $368 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $426 · 2023: $386 · 2024: $484 · 2025: $368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,237.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $246.65 | 2023-2025 | Jardiance, Mounjaro, Trulicity |
| Abbott Laboratories | $215.08 | 2023-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $160.72 | 2022 | |
| Corcept Therapeutics | $158.12 | 2023-2025 | Korlym |
| Novo Nordisk INC | $115.45 | 2023-2025 | Ozempic, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $108.80 | 2022 | |
| Pfizer INC. | $98.58 | 2022 | |
| Sanofi-Aventis U.S. LLC | $92.50 | 2023-2025 | |
| Amgen INC. | $91.39 | 2025 | Tepezza |
| Xeris Pharmaceuticals, INC. | $68.48 | 2023-2024 | Recorlev |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $47.92 | 2022-2023 | Lifevest |
| Sequel Med Tech, LLC | $44.60 | 2025 | Twiist |
| Tandem Diabetes Care, INC. | $40.90 | 2023-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic, INC. | $39.98 | 2024 | Minimed 780g |
| Insulet Corporation | $30.63 | 2025 | Omnipod |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $24.56 | 2022 | |
| Abbvie INC. | $22.29 | 2024 | |
| Ascendis Pharma Endocrinology INC | $22.13 | 2023 | |
| Recordati_rare_diseases_inc. | $18.55 | 2025 | Isturisa |
| Mannkind Corporation | $16.94 | 2023 | Afrezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Misha Masumy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.